GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Loxo Oncology Inc (NAS:LOXO) » Definitions » Quick Ratio

Loxo Oncology (Loxo Oncology) Quick Ratio : 3.62 (As of Sep. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Loxo Oncology Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Loxo Oncology's quick ratio for the quarter that ended in Sep. 2018 was 3.62.

Loxo Oncology has a quick ratio of 3.62. It generally indicates good short-term financial strength.

The historical rank and industry rank for Loxo Oncology's Quick Ratio or its related term are showing as below:

LOXO's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.515
* Ranked among companies with meaningful Quick Ratio only.

Loxo Oncology Quick Ratio Historical Data

The historical data trend for Loxo Oncology's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Loxo Oncology Quick Ratio Chart

Loxo Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
Quick Ratio
36.61 60.31 54.91 9.36 3.53

Loxo Oncology Quarterly Data
Sep13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.56 3.53 3.52 3.64 3.62

Competitive Comparison of Loxo Oncology's Quick Ratio

For the Biotechnology subindustry, Loxo Oncology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Loxo Oncology's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Loxo Oncology's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Loxo Oncology's Quick Ratio falls into.



Loxo Oncology Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Loxo Oncology's Quick Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Quick Ratio (A: Dec. 2017 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(781.807-0)/221.57
=3.53

Loxo Oncology's Quick Ratio for the quarter that ended in Sep. 2018 is calculated as

Quick Ratio (Q: Sep. 2018 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(628.308-0)/173.769
=3.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Loxo Oncology  (NAS:LOXO) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Loxo Oncology Quick Ratio Related Terms

Thank you for viewing the detailed overview of Loxo Oncology's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Loxo Oncology (Loxo Oncology) Business Description

Traded in Other Exchanges
N/A
Address
Loxo Oncology Inc develops medicines for patients with genetically defined cancers. Its approach is based on the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building inhibitors against single targets in the cancer cell. Its pipeline of products includes Larotrectinib, Loxo etc.
Executives
Jennifer Burstein officer: Senior VP of Finance C/O LOXO ONCOLOGY, INC., ONE LANDMARK SQUARE, SUITE 1122, STAMFORD CT 06901
Keith T. Flaherty director 55 FRUIT STREET, YAWKEY 9E, BOSTON MA 02114
Lori Anne Kunkel director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Joshua H. Bilenker director, officer: President & CEO C/O LOXO ONCOLOGY, INC., ONE LANDMARK SQUARE, SUITE 1122, STAMFORD CT 06901
Steve Elms director, 10 percent owner 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Alan Fuhrman director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Andrew N Schiff 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Dennis J Purcell 10 percent owner AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Aisling Capital Iii Lp 10 percent owner 888 Seventh Avenue, 30th Fl, New York NY 10106
Aisling Capital Partners Iii Lp 10 percent owner AISLING CAPITAL LLC, 888 SEVENTH AVENUE 30TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iii Llc 10 percent owner AISLING CAPITAL LLC, 888 SEVENTH AVENUE 30TH FLOOR, NEW YORK NY 10106
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp V Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Loxo Oncology (Loxo Oncology) Headlines

From GuruFocus

Loxo Oncology to Announce Second Quarter 2018 Financial Results

By Marketwired Marketwired 08-02-2018

5 Health Care Stocks in Gurus' Portfolios

By Tiziano Frateschi Tiziano Frateschi 09-06-2018